T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.47B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.73B |
| 3 |
Tesla
TSLA
|
+$1.7B |
| 4 |
Northrop Grumman
NOC
|
+$1.67B |
| 5 |
Dollar Tree
DLTR
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.85B |
| 3 |
Texas Instruments
TXN
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.27B |
| 5 |
Booking.com
BKNG
|
+$1.18B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.76% |
| 2 | Technology | 16.79% |
| 3 | Consumer Discretionary | 15.26% |
| 4 | Financials | 14.49% |
| 5 | Industrials | 9.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
iShares Core MSCI EAFE ETF
IEFA
$196B
| $4.91M | ﹤0.01% |
76,541
+60,844
| +388% | +$3.88M |
|
1452
Qiagen
QGEN
$8.93B
| $4.89M | ﹤0.01% |
+121,675
| New | +$4.86M |
|
|
ODT
1453
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $4.87M | ﹤0.01% |
+250,671
| New | +$5.11M |
|
1454
Senseonics Holdings Inc
SENS
$409M
| $4.84M | ﹤0.01% |
50,771
+29
| +0.1% | +$2.37K |
|
1455
Cardlytics
CDLX
$25.1M
| $4.82M | ﹤0.01% |
+19,238
| New | +$4.14M |
|
1456
Range Resources
RRC
$9.33B
| $4.79M | ﹤0.01% |
281,623
+9,205
| +3% | +$148K |
|
1457
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.9B
| $4.75M | ﹤0.01% |
55,000
+20,000
| +57% | +$1.72M |
|
1458
Arbutus Biopharma
ABUS
$906M
| $4.7M | ﹤0.01% |
+497,328
| New | +$4.94M |
|
1459
Voyager Therapeutics
VYGR
$198M
| $4.59M | ﹤0.01% |
242,434
+209,580
| +638% | +$4.02M |
|
|
CBAY
1460
DELISTED
Cymabay Therapeutics
CBAY
| $4.55M | ﹤0.01% |
410,967
-276,310
| -40% | -$3.43M |
|
1461
Hudbay
HBM
$11.8B
| $4.54M | ﹤0.01% |
896,318
+79,167
| +10% | +$392K |
|
1462
Applied Industrial Technologies
AIT
$13.2B
| $4.52M | ﹤0.01% |
57,708
-13,374
| -19% | -$1.01M |
|
1463
Chemours
CC
$2.3B
| $4.49M | ﹤0.01% |
113,922
+10,841
| +11% | +$474K |
|
|
QVCGA
1464
DELISTED
QVC Group Inc Series A
QVCGA
| $4.44M | ﹤0.01% |
4,121
-30
| -0.7% | -$31.5K |
|
1465
Wyndham Hotels & Resorts
WH
$5.51B
| $4.32M | ﹤0.01% |
77,646
+1,161
| +2% | +$66.4K |
|
1466
Arch Capital
ACGL
$33.5B
| $4.31M | ﹤0.01% |
144,526
+744
| +0.5% | +$22.1K |
|
1467
EverQuote
EVER
$864M
| $4.28M | ﹤0.01% |
288,258
-36,742
| -11% | -$557K |
|
1468
SEI Investments
SEIC
$12.8B
| $4.24M | ﹤0.01% |
69,389
+1,041
| +2% | +$64.5K |
|
|
EV
1469
DELISTED
Eaton Vance Corp.
EV
| $4.2M | ﹤0.01% |
79,976
+124
| +0.2% | +$6.57K |
|
|
ZOES
1470
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $4.14M | ﹤0.01% |
325,512
-3,197
| -1% | -$36.4K |
|
1471
Gaming and Leisure Properties
GLPI
$12.7B
| $4.1M | ﹤0.01% |
116,232
+381
| +0.3% | +$13.5K |
|
|
TPIC
1472
DELISTED
TPI Composites
TPIC
| $4.09M | ﹤0.01% |
143,408
+121,422
| +552% | +$3.52M |
|
|
MRNS
1473
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.09M | ﹤0.01% |
+102,165
| New | +$2.91M |
|
1474
iShares Core S&P 500 ETF
IVV
$910B
| $4.07M | ﹤0.01% |
13,886
+6,132
| +79% | +$1.76M |
|
1475
KALA BIO
KALA
$17.9M
| $4.06M | ﹤0.01% |
+165
| New | +$5.03M |
|
Similar funds
T. Rowe Price Associates's Q3 2018 Portfolio in Review
As of Q3 2018, T. Rowe Price Associates held 2,658 positions worth $685B, up 4.7% from $654B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q3 2018 filing shows 77 new, 1,268 increased, 1,098 reduced and 77 closed positions. Its largest new stake was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M. The largest sale was Broadcom, an estimated $3.29B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2018 buy was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M.
- T. Rowe Price Associates added most to NVIDIA in Q3 2018, an estimated $2.47B increase.
- T. Rowe Price Associates's biggest Q3 2018 reduction was Broadcom, cutting an estimated $3.29B.
- T. Rowe Price Associates fully exited DCT Industrial Trust Inc. in Q3 2018, selling an estimated $345M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $685B portfolio in Q3 2018.
- T. Rowe Price Associates opened 77 new positions and closed 77 in Q3 2018.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $685B.
Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.